| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911316 | Lung Cancer | 2012 | 5 Pages |
Abstract
No evidence of an improvement in event-free survival was seen with the addition of weekly gemcitabine at this dose for patients with early stage NSCLC unfit for surgery, although the power of the study was low.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Allan Price, Ann Yellowlees, Catriona Keerie, Susan Russell, Corinne Faivre-Finn, David Gilligan, Michael Snee, Geraldine Skailes, Matthew Hatton, Sara Erridge, Nazia Mohammed,